Karyopharm Therapeutics (NASDAQ:KPTI) Earns Buy Rating from HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $7.00 price target on the stock.

A number of other research firms have also recently issued reports on KPTI. Piper Sandler raised their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $0.70 on Wednesday. The stock has a 50-day simple moving average of $0.75 and a 200 day simple moving average of $0.81. The stock has a market capitalization of $88.12 million, a P/E ratio of -0.61 and a beta of 0.07. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter in the prior year, the firm posted ($0.30) earnings per share. Research analysts forecast that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP increased its position in Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after acquiring an additional 792,283 shares during the period. AQR Capital Management LLC grew its position in shares of Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after purchasing an additional 622,194 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $494,000. Acadian Asset Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $167,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $143,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).